Human life is often portrayed across the board as a piece of unbeatable utopia, and in all honesty, there is indeed some truth in that representation. After all, which other species can boast the luxuries we do in regards to both superiority and volume? However, while we duly acknowledge our privileges, we must not become unaware of our challenges. For instance, human life is under constant pressure to replenish everything time and again. This ensures that our holistic perspective doesn’t go stagnant, and alongside the said benefit, it also ends up transitioning us to a situation much better than anything we had a chance to experience before. Now, it’s good to have such an influential system in place, but at the same time, when every emerging result offers ridiculous value, it gets really hard to segregate the impact of different attempts. Fortunately, there isn’t a debate on which attempt made the strongest impact, as technology takes that honor home quite comfortably. If we talk about technology’s case within the established context, we just have to turn around and see how the creation has altered our surroundings so significantly. The world we used to know is a mere distant memory now, and all for good reason. Today, owing to the technological prowess at our disposal, we can successfully sustain a far more refined brand of lifestyle. The trend has also seeped in and around granular levels, covering every major sector out there. Nevertheless, the need of keeping things fresh through a continuous push towards change still remains integral to our existence. One organization that seemingly understands this assignment well is Quidel.
Quidel, a leading point-of-care products’ manufacturer, has officially acquired Ortho Clinical Diagnostics in a deal worth $6 billion. According to certain reports, the financial structure of the acquisition involves $24.68 per common stock share, which is constructed using cash and shares in the new and expanded Quidel entity. Both the companies now plan on targeting what would be consolidated market potential of over $50 billion. Apart from the financial prospects, there is also a major geographical incentive driving up the deal. Using Ortho’s footprint in nearly 130 countries, Quidel intends to scale up and go beyond the boundaries of its current discipline.
“The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services that enhance the health and well-being of patients across the globe,” said Douglas Bryant, Quidel President & CEO.
Even though the deal is largely growth-oriented, it also somewhat rooted in Quidel’s fear of regression once the urgency around Covid 19 is over. Hence, the newly-gained access of Ortho’s antigen, antibody, quantitative body, nucleocapsid and spike antibody tests, along with many more, should help Quidel in achieving some much-needed diversification over the long-term.
